RT Journal Article
SR Electronic
T1 Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 159
OP 164
VO 32
IS 1
A1 PAOLO BORGHETTI
A1 MARCO LORENZO BONÙ
A1 ELISA ROCA
A1 SARA PEDRETTI
A1 EMILIANO SALAH
A1 ANNA BAIGUINI
A1 DIANA GRECO
A1 LUCA TRIGGIANI
A1 MARTA MADDALO
A1 NICCOLÒ GIAJ LEVRA
A1 FILIPPO ALONGI
A1 STEFANO MARIA MAGRINI
A1 MICHELA BUGLIONE
YR 2018
UL http://iv.iiarjournals.org/content/32/1/159.abstract
AB Aim: To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC). Patients and Methods: Fifty patients with EGFR-mutated or ALK rearrangement-positive NSCLC were treated at our Institution. Radiotherapy was delivered before, after or concomitantly with tyrosine kinase inhibitors (TKIs). Acute toxicities and overall survival (OS) were assessed. Results: Radiotherapy was performed within 30 days before TKI, concomitantly with TKI and within 30 days after TKI in eight (16%), 33 (66%) and 9 (18%) cases, respectively. The median duration of TKI therapy in the whole series was 11.9 months. The median OS was 19.3 months and 1- and 2-year OS was 71.5% and 36.5%, respectively. The group treated with SBRT had a significant benefit in terms of OS (p=0.043). Only two grade 3 toxicities were reported. Conclusion: RT concomitantly or close to TKI administration in stage IV NSCLC was shown to be feasible and safe. Intriguing data on OS were also reported.